Clinical Trials Logo

Coronary Artery Disease clinical trials

View clinical trials related to Coronary Artery Disease.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT04834843 Completed - Clinical trials for Coronary Artery Disease

Temporal Trends of COronary Artery Disease and PEripheral Artery Disease (COPE) in Korea

COPE registry
Start date: January 1, 2009
Study type: Observational

Cardiovascular disease (CVD) is caused by atherosclerosis of the artery and is classified into coronary artery disease, cerebrovascular disease, and peripheral arterial disease, depending on the location of the artery and the target organs. However, since CVD share a similar pathophysiology and the probability of incidence of other CVD in CVD patients is very high. It is thought that CVD incidence and mortality can be reduced by predicting the degree of incidence of other CVD in CVD patients. The aim of this study is to investigate the incidence and mortality of other CVD diseases in CVD patients.

NCT ID: NCT04825795 Completed - Diabetes Mellitus Clinical Trials

DPP4i and Coronary Atherosclerosis in Patients Receiving Insulin Therapy

Start date: January 1, 2010
Study type: Observational

The study aim is to evaluate whether DPP4-inhibitor could reduce coronary atherosclerosis assessed by CT scan in patients receiving insulin for diabetes mellitus. In this retrospective study, change in coronary calcium burden between two coronary CT scan will be compared in patients with and without receiving DPP4-inhibitor.

NCT ID: NCT04785846 Completed - Clinical trials for Acute Coronary Syndrome

Registry of RESOLUTE-ONYX™ Zotarolimus-eluting Stent Utilization in Percutaneous Small Vessel Coronary Interventionism.

Start date: October 18, 2017
Study type: Observational [Patient Registry]

DESIGN: Prospective, single-arm, multicenter, observational, prospective registry of the use of the RESOLUTE-ONYX™ zotarolimus-eluting stent in percutaneous coronary intervention in small vessels. Clinical follow-up at 1 month, 6 months and 1 year. OBJECTIVE: To evaluate the safety and efficacy of using RESOLUTE-ONYX zotarolimus-eluting stent in PCI in small vessels (diameter ≤2.5 mm). DISEASE UNDER STUDY: Adult patients with coronary artery disease (stable angina, silent ischemia or non-ST-segment elevation acute coronary syndrome) undergoing percutaneous coronary intervention on vessels with a diameter less than or equal to 2.5 mm. TOTAL NUMBER OF PATIENTS: Approximately 320 patients are expected to be included in the study.

NCT ID: NCT04784702 Completed - Clinical trials for Coronary Artery Disease

Smoking Cessation in Patients After Coronary Angiography

Start date: August 5, 2014
Study type: Observational

OBJECTIVES The goal of this study is to evaluate the self-achieved smoking cessation supported with cytisine smoking cessation and its' on platelet aggregation and prothrombotic state in patients after coronary angiography and PCI. BACKGROUND Cigarette smoking is a major risk factor of coronary artery disease (CAD). Smoking cessation is one of the most cost-effective intervention in lifestyle. Self-reported rates of smoking cessation are reasonably low. Cytisine is promising drug in support of smoking cessation. Smoking affects various components leading to arterial thrombosis, and the effect of smoking cessation on prothrombotic state and platelet aggregation is still under investigation GOAL To assess rates of smoking cessation in patients after coronary angiography and PCI and factors influencing success in smoking cessation To assess feasibility, safety and efficacy of cytisine in smoking patients To assess effect of smoking cessation on platelet aggregation in patients treated with clopidogrel and on prothrombotic state. METHODS A prospective nonrandomized observational study of patients after coronary angiography.

NCT ID: NCT04772924 Completed - Clinical trials for Coronary Artery Disease

Long-term Fasting in Patients With a History of PCI

Start date: April 20, 2020
Phase: N/A
Study type: Interventional

Patients in this prospective cohort study were selected if they had a history of PCI more than 1 year previously. 405 patients were divided based on their preferences to fasting and non fasting and after 1 month of fasting major adverse cardiovascular events were measured

NCT ID: NCT04754880 Completed - Clinical trials for Coronary Artery Disease

Coronary Chronic Total Occlusion and Oxidative Balance

Start date: January 1, 2018
Study type: Observational

The presence of chronic blockage of coronary arteries, which we may accept as the terminal point of atherosclerotic coronary artery disease, is closely associated with a poor prognosis. The Discovery of markers that may distinguish patients with a high risk of chronic total occlusion development among patients monitored with the diagnosis of stable coronary artery disease may be important for being able to reduce the increased mortality and morbidity rates. Oxidative stress status may be one of the markers that play a role in and/or show the development of chronic total occlusion. It was reported that it has a role in the progression, erosion, and instability of atherosclerotic plaques in coronary arteries. To the best of our knowledge, the relationship between chronic total occlusion development and oxidative stress status in stable coronary artery disease has not been studied. This study investigated the relationships in the oxidative stress status evaluated over TAS, TOS, OSI, Thiol/Disulfide Homeostasis, and antioxidative vitamin levels and possible differences in patients with noncritical coronary artery disease and those with chronic total occlusion.

NCT ID: NCT04741022 Completed - Clinical trials for Coronary Artery Disease

Influence of Obstructive Sleep Apnea on the Severity of Coronary Artery Disease

Start date: February 14, 2017
Study type: Observational [Patient Registry]

It is widely accepted that coronary artery disease (CAD) is related to a high mortality. It is predicted that an increase of approximately 21.3 million cardiovascular events and 7.7 million cardiovascular deaths over 2010 to 2030 in China.1 Male sex, diabetes mellitus, hypertension, hypercholesterolemia, obesity and smoking are all traditionally considered as risk factors for CAD. In recent decades, tremendous progress toward the prevention and treatment of traditional cardiovascular risk factors have helped decrease the morbidity and mortality from CAD, but the condition remains a major public health challenge worldwide. Looking into the other potential risk factors (OSA) for CAD, it may help to develop additional preventative strategies and further reduce the incidence and mortality of CAD.

NCT ID: NCT04731285 Completed - Clinical trials for Coronary Artery Disease

Evaluation of Accuracy of CFD-based RuiXin-FFR by Comparing With Pressure-wire-based FFR

Start date: October 13, 2017
Study type: Observational

Coronary Artery Disease (CAD) is the top killer nowadays. Pressure-wire-based Fractional Flow Reserve (FFR) is the gold standard for measuring ischemia in coronary arteries. CFD-based RuiXin-FFR, which is noninvasive, is developed recently. But its accuracy and effectiveness is not verified by a clinical trial. This is a multi-center and prospective trial. The primary end point is the measurement of sensitivity and specificity of CFD-based RuiXin-FFR.

NCT ID: NCT04703439 Completed - Clinical trials for Coronary Heart Disease

An mHealth Intervention to Improve Medication Adherence and Health Outcomes

Start date: May 20, 2018
Phase: N/A
Study type: Interventional

Investigators evaluated the efficacy of a pilot-tested mHealth intervention to improving medication adherence and health outcomes among patients with coronary heart disease.

NCT ID: NCT04667832 Completed - Clinical trials for Coronary Artery Disease

ABI for Screening of Coronary Artery Disease

Start date: March 1, 2019
Study type: Observational [Patient Registry]

Large population cross sectional study between 2019-2020 for 4207 new patients that refer to professor Kojuri cardiovascular clinic in shiraz, Iran, was conducted. Patients were undergone selective coronary angiography from radial artery approach by an expert interventional cardiologist. ABI were measured for all patients. ABI ratio was compared with the results of coronary angiography for patients who underwent coronary angiography to measure specificity and sensitivity.